Article
IFN-γ and TNF-α Pre-licensing Protects Mesenchymal Stromal Cells from the Pro-inflammatory Effects of Palmitate.
Molecular therapy : the journal of the American Society of Gene Therapy - 7 Mar 2018
Boland Lauren, Burand Anthony J, Brown Alex J, Boyt Devlin, Lira Vitor A, Ankrum James A
Abstract excerpt
The use of mesenchymal stromal cell (MSC) therapy for the treatment of type 2 diabetes (T2D) and T2D complications is promising; however, the investigation of MSC function in the setting of T2D has not been thoroughly explored. In our current study, we investigated the phenotype and function of MSCs in a simulated in vitro T2D environment. We show that palmitate, but not glucose, exposure impairs MSC metabolic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
